Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220636 · ClinicalTrials.gov registry record · Phase 4
Abilify as an Adjunctive Treatment for Refractory Depression
A Phase 4 study of Depressive Disorder, Major, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00220636 is a Phase 4 study of Depressive Disorder, Major that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 15 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00220636, a Phase 4 study of Depressive Disorder, Major, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (1)
New York
- Depression Evaluation Service, NY State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220636
The ClinicalTrials.gov registry entry for NCT00220636 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (94% lower). The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00220636 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00220636 about?
NCT00220636 is a clinical study titled "Abilify as an Adjunctive Treatment for Refractory Depression". This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patie...
What is the current status of trial NCT00220636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2005-03. Estimated completion is 2008-01.
What conditions does trial NCT00220636 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT00220636?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00220636?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00220636 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
RECRUITING
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.